BRPI0907162A2 - Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamífero - Google Patents
Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamíferoInfo
- Publication number
- BRPI0907162A2 BRPI0907162A2 BRPI0907162-8A BRPI0907162A BRPI0907162A2 BR PI0907162 A2 BRPI0907162 A2 BR PI0907162A2 BR PI0907162 A BRPI0907162 A BR PI0907162A BR PI0907162 A2 BRPI0907162 A2 BR PI0907162A2
- Authority
- BR
- Brazil
- Prior art keywords
- performer
- mammal
- treating
- compound
- methods
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 title 1
- 230000003213 activating effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/12—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2060808P | 2008-01-11 | 2008-01-11 | |
| PCT/US2009/030680 WO2009089508A1 (en) | 2008-01-11 | 2009-01-09 | Activators of executioner procaspases 3, 6 and 7 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0907162A2 true BRPI0907162A2 (pt) | 2015-07-07 |
Family
ID=40853483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0907162-8A BRPI0907162A2 (pt) | 2008-01-11 | 2009-01-09 | Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamífero |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8642788B2 (pt) |
| EP (1) | EP2237784A1 (pt) |
| JP (1) | JP2011509939A (pt) |
| CN (1) | CN101965189A (pt) |
| AU (1) | AU2009203977A1 (pt) |
| BR (1) | BRPI0907162A2 (pt) |
| CA (1) | CA2711603A1 (pt) |
| EA (1) | EA201001143A1 (pt) |
| IL (1) | IL206901A0 (pt) |
| MX (1) | MX2010007548A (pt) |
| WO (1) | WO2009089508A1 (pt) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104080780B (zh) * | 2011-11-30 | 2018-04-13 | 索尔维公司 | 氟化的麦德鲁姆酸的衍生物、其制备方法、及其作为溶剂添加剂的用途 |
| AU2013225682B2 (en) * | 2012-03-02 | 2016-04-14 | The Board Of Trustees Of The University Of Illinois | Potent anticancer activity via dual compound activation |
| CA2866021C (en) | 2012-03-06 | 2020-09-22 | The Board Of Trustees Of The University Of Illinois | Procaspace 3 activation by pac-1 combination therapy |
| AU2013230985B2 (en) | 2012-03-06 | 2016-05-12 | The Board Of Trustees Of The University Of Illinois | Procaspase combination therapy for glioblastoma |
| JP6404220B2 (ja) | 2012-09-27 | 2018-10-10 | シャンドーン イーンドーン イーンハオ バイオテクノロジー，インコーポレイティド | テアニン誘導体とカルボン酸クマリン誘導体との縮合生成物、その中間体、調製方法、及びその使用 |
| PL2953942T3 (pl) | 2013-02-06 | 2018-03-30 | Bayer Cropscience Aktiengesellschaft | Podstawione halogenem pochodne pirazolu jako środki do zwalczania szkodników |
| JP6678581B2 (ja) | 2013-11-27 | 2020-04-08 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ | ５−フルオロ−１ｈ−ピラゾール類の調製のための方法 |
| MX2016008653A (es) | 2014-01-03 | 2016-09-26 | Bayer Animal Health Gmbh | Nuevas pirazolil-heteroarilamidas como agentes plaguicidas. |
| ES2750353T3 (es) | 2014-08-19 | 2020-03-25 | Bayer Animal Health Gmbh | Procedimiento de preparación de 5-fluoro-1H-pirazoles partiendo de hexafluoropropeno |
| BR112017019266B1 (pt) | 2015-03-10 | 2022-05-10 | Bayer Animal Health Gmbh | Compostos derivados de pirazolila e composição farmacêutica compreendendo o referido composto |
| EP3133065A1 (en) | 2015-08-21 | 2017-02-22 | Merck Patent GmbH | Compounds for optically active devices |
| EP3363786A1 (en) | 2017-02-15 | 2018-08-22 | Merck Patent GmbH | Compounds for optically active devices |
| EP3363793A1 (en) | 2017-02-15 | 2018-08-22 | Merck Patent GmbH | Hydrophobic compounds for optically active devices |
| CN106946897B (zh) * | 2017-02-28 | 2018-10-23 | 牡丹江医学院 | 一种治疗胆囊炎的药物及其应用 |
| AU2018368453B2 (en) | 2017-11-17 | 2024-05-30 | The Board Of Trustees Of The University Of Illinois | Cancer therapy by degrading dual MEK signaling |
| CA3114385A1 (en) | 2018-10-05 | 2020-04-09 | The Board Of Trustees Of The University Of Illinois | Combination therapy for the treatment of uveal melanoma |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| KR102797127B1 (ko) * | 2018-12-29 | 2025-04-21 | 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 | 헤테로고리계 화합물, 중간체, 이의 제조 방법 및 용도 |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| CA3150681A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| US11851426B2 (en) | 2019-10-11 | 2023-12-26 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| EP4081209A4 (en) * | 2019-12-24 | 2024-04-24 | The Regents of the University of California | Compositions and methods for treating cancer and improving epithelial homeostasis |
| US20230203214A1 (en) | 2020-05-20 | 2023-06-29 | Merck Patent Gmbh | Azacoumarin and azathiocoumarin derivatives for use in optically active devices |
| CN113024499A (zh) * | 2021-03-17 | 2021-06-25 | 河南中烟工业有限责任公司 | 一种香豆素-3-羧酸类化合物的绿色合成方法 |
| US20240300939A1 (en) | 2021-06-14 | 2024-09-12 | Scorpion Therapeutics, Inc. | Urea derivatives which can be used to treat cancer |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| WO2024129896A1 (en) * | 2022-12-14 | 2024-06-20 | The Regents Of The University Of California | Inhibitors of procaspase-6 activation and uses thereof |
| CN117186001B (zh) * | 2023-09-07 | 2024-09-17 | 南京中医药大学 | 一种具有抗多发性骨髓瘤活性的aha1抑制剂及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000006550A1 (en) * | 1998-07-31 | 2000-02-10 | Nippon Soda Co., Ltd. | Phenylazole compounds, process for producing the same and drugs for hyperlipemia |
| EP1310488A4 (en) * | 2000-08-09 | 2005-08-10 | Mitsubishi Pharma Corp | CONCENTRATED BICYCLIC AMID COMPOUNDS AND THEIR MEDICAL USE |
| US20030229132A1 (en) | 2002-02-12 | 2003-12-11 | Jack Nguyen | Small molecule modulators of apoptosis |
| KR100440588B1 (ko) * | 2002-06-10 | 2004-07-19 | 한국전자통신연구원 | 계층적 구조를 지원하는 직렬 버스형 형상 인식 및 경보장치 |
| WO2007124617A1 (fr) * | 2006-04-28 | 2007-11-08 | Institute Of Mataria Medica, Chinese Academy Of Medical Sciences | Dérivés de coumarine, leurs procédés de préparation, compositions pharmaceutiques et utilisations |
| WO2009086303A2 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
-
2009
- 2009-01-09 MX MX2010007548A patent/MX2010007548A/es not_active Application Discontinuation
- 2009-01-09 CN CN2009801088905A patent/CN101965189A/zh active Pending
- 2009-01-09 BR BRPI0907162-8A patent/BRPI0907162A2/pt not_active IP Right Cessation
- 2009-01-09 US US12/812,360 patent/US8642788B2/en not_active Expired - Fee Related
- 2009-01-09 EA EA201001143A patent/EA201001143A1/ru unknown
- 2009-01-09 WO PCT/US2009/030680 patent/WO2009089508A1/en not_active Ceased
- 2009-01-09 AU AU2009203977A patent/AU2009203977A1/en not_active Abandoned
- 2009-01-09 EP EP09701320A patent/EP2237784A1/en not_active Withdrawn
- 2009-01-09 CA CA2711603A patent/CA2711603A1/en not_active Abandoned
- 2009-01-09 JP JP2010542395A patent/JP2011509939A/ja not_active Withdrawn
-
2010
- 2010-07-08 IL IL206901A patent/IL206901A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101965189A (zh) | 2011-02-02 |
| MX2010007548A (es) | 2010-11-25 |
| JP2011509939A (ja) | 2011-03-31 |
| AU2009203977A1 (en) | 2009-07-16 |
| EA201001143A1 (ru) | 2011-02-28 |
| EP2237784A1 (en) | 2010-10-13 |
| IL206901A0 (en) | 2010-12-30 |
| US20110021522A1 (en) | 2011-01-27 |
| US8642788B2 (en) | 2014-02-04 |
| WO2009089508A1 (en) | 2009-07-16 |
| CA2711603A1 (en) | 2009-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0907162A2 (pt) | Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamífero | |
| BRPI0921317A2 (pt) | composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero | |
| BRPI0813725A2 (pt) | Métodos e composições para tratamento de doenças | |
| BRPI0812521A2 (pt) | Composto, composição farmacêutica, método para o tratamento de doença em um mamífero, processo para a preparação de um composto, e, uso de um composto | |
| BRPI0921687A2 (pt) | Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero. | |
| EP1868628A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING POCKET VIRUS INFECTIONS | |
| BRPI0908503A2 (pt) | partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos | |
| BRPI0918652A2 (pt) | Composições farmacêuticas e métodos de libração relacionadas. | |
| BRPI0812851A2 (pt) | Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto | |
| BRPI0813011A2 (pt) | Formulação injetável aquosa estéril, processo de preparação da mesma e sua utilização | |
| CR10667A (es) | Compositions and methods for diagnosing and treating cancer | |
| BRPI0915284A2 (pt) | Composição famacêutica oral, método para tratar uma infecção fúngica e para tratar câncer em um mamífero, e, formulação de liberação prolongada oral | |
| BRPI0809655A2 (pt) | Método para tratar uma condição em um mamífero, composição farmacêutica, e, kit | |
| BRPI0819218A2 (pt) | Métodos, estojos e composições para administração de compostos farmacêuticos | |
| BRPI0809890A2 (pt) | Processo para preparar imatinib ou sal do mesmo e composição farmacêutica | |
| BRPI0618845A2 (pt) | composto, formulação farmacêutica, uso de um composto, e, métodos para a inibição da atividade de bace e para o tratamento ou a prevenção de uma patologia relacionada a abeta em um mamífero | |
| BRPI0912245A2 (pt) | composto, prodroga, medicamento, métodos de suprimir produção de açúcar em um mamífero e para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso do composto | |
| BRPI0813212A2 (pt) | Métodos de tratamento de doenças e distúrbios mediados por serotonina | |
| EP1981512A4 (en) | MODIFIED MACROMOLEKÜL | |
| CA2645871A1 (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OXALATE-ASSOCIATED DISEASE | |
| BRPI0911681A2 (pt) | composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula | |
| BRPI0917705A2 (pt) | composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto | |
| BRPI0906805A2 (pt) | Composto, processo para preparar o enanciômero puro, composição farmacêutica, uso do enanciômero puro, métodos para prevenir ou tratar doença em um animal de sangue quente, e, combinação | |
| BRPI0907977A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| PT2868315T (pt) | Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |